Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine XR in Adults With ADHD and Emotional Dysregulation
NCT07759154Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 3 trial of centanafadine in attention deficit hyperactivity disorder (ADHD), emotional dysregulation, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2026; status: recruiting.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)emotional dysregulation
Beyond the preview
Go deeper on NCT07759154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07759154.